Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Short Interest Update

Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) was the target of a significant drop in short interest during the month of March. As of March 13th, there was short interest totaling 10,137,184 shares, a drop of 15.4% from the February 26th total of 11,984,360 shares. Based on an average daily volume of 356,307 shares, the days-to-cover ratio is currently 28.5 days. Approximately 22.3% of the company’s shares are short sold.

Insider Activity

In other Immunocore news, insider David M. Berman sold 5,965 shares of the firm’s stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $32.35, for a total value of $192,967.75. Following the sale, the insider directly owned 5,859 shares of the company’s stock, valued at approximately $189,538.65. This trade represents a 50.45% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Leger Tina Amber St sold 1,000 shares of Immunocore stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $32.35, for a total value of $32,350.00. Following the completion of the sale, the insider owned 1,119 shares of the company’s stock, valued at $36,199.65. This trade represents a 47.19% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 19,137 shares of company stock valued at $619,082 over the last quarter. Company insiders own 10.40% of the company’s stock.

Institutional Investors Weigh In On Immunocore

Several large investors have recently made changes to their positions in IMCR. Leonteq Securities AG acquired a new position in shares of Immunocore during the 4th quarter valued at $30,000. GAMMA Investing LLC increased its holdings in Immunocore by 51.6% in the 3rd quarter. GAMMA Investing LLC now owns 914 shares of the company’s stock valued at $33,000 after purchasing an additional 311 shares in the last quarter. Harbour Investments Inc. increased its holdings in Immunocore by 60.2% in the 4th quarter. Harbour Investments Inc. now owns 1,033 shares of the company’s stock valued at $36,000 after purchasing an additional 388 shares in the last quarter. Elevation Point Wealth Partners LLC purchased a new position in Immunocore in the second quarter valued at about $42,000. Finally, Rockefeller Capital Management L.P. acquired a new position in shares of Immunocore during the fourth quarter worth about $47,000. Institutional investors and hedge funds own 84.50% of the company’s stock.

Analyst Upgrades and Downgrades

IMCR has been the topic of several recent analyst reports. Mizuho set a $38.00 price objective on shares of Immunocore in a report on Thursday, February 19th. Weiss Ratings restated a “sell (e+)” rating on shares of Immunocore in a report on Thursday, January 22nd. UBS Group set a $55.00 price target on shares of Immunocore and gave the stock a “buy” rating in a research report on Wednesday, January 7th. HC Wainwright reaffirmed a “buy” rating and set a $100.00 price target on shares of Immunocore in a research note on Wednesday, February 4th. Finally, Wall Street Zen lowered shares of Immunocore from a “buy” rating to a “hold” rating in a report on Saturday, January 31st. Seven research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $59.80.

Immunocore Stock Performance

Immunocore stock opened at $30.31 on Thursday. The company has a market cap of $1.54 billion, a price-to-earnings ratio of -43.30 and a beta of 0.83. Immunocore has a 12 month low of $23.15 and a 12 month high of $40.71. The company has a debt-to-equity ratio of 1.03, a current ratio of 4.04 and a quick ratio of 4.01. The stock’s 50-day moving average is $32.08 and its 200-day moving average is $33.91.

Immunocore (NASDAQ:IMCR) last issued its earnings results on Saturday, February 14th. The company reported ($0.60) earnings per share (EPS) for the quarter. Immunocore had a negative return on equity of 9.20% and a negative net margin of 8.88%.The firm had revenue of $104.48 million for the quarter. Equities analysts anticipate that Immunocore will post -0.94 earnings per share for the current year.

About Immunocore

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.